Free tool
FAERS Monitor: Vyloy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761365 or its brand name (Vyloy, Zolbetuximab-Clzb). Reports on generic versions are filed under their own applications.
Reports
1,525
Serious
1,304
86% of reports
Hospitalization
515
Death reported
178
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea558
- vomiting271
- decreased appetite201
- ascites138
- hypoalbuminaemia129
- malignant neoplasm progression117
- blood albumin decreased100
- diarrhoea82
- oedema peripheral67
- myelosuppression66
- neutrophil count decreased63
- malaise62
- oedema53
- abdominal pain51
- dehydration49
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 22 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 100 |
| 2025 | 772 |
| 2026 | 607 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,634 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoalbuminaemiaSignal | 129 | 232.8 | 197.1 | 29,066 |
| blood albumin decreasedSignal | 100 | 176.1 | 145.5 | 17,022 |
| ascitesSignal | 138 | 65.0 | 55.5 | 8,610 |
| myelosuppressionSignal | 66 | 25.3 | 20.0 | 1,517 |
| neutrophil count decreasedSignal | 63 | 21.4 | 16.8 | 1,202 |
| malignant neoplasm progressionSignal | 117 | 15.8 | 13.3 | 1,610 |
| oedemaSignal | 53 | 13.5 | 10.4 | 601 |
| decreased appetiteSignal | 201 | 11.9 | 10.5 | 2,025 |
| nauseaSignal | 558 | 9.7 | 9.1 | 4,529 |
| vomitingSignal | 271 | 8.0 | 7.1 | 1,677 |
| oedema peripheralSignal | 67 | 7.6 | 6.0 | 378 |
| dehydrationSignal | 49 | 5.1 | 3.8 | 157 |
| abdominal painSignal | 51 | 3.0 | 2.3 | 68 |
| malaise | 62 | 1.9 | 1.5 | 28 |
| diarrhoea | 82 | 1.8 | 1.4 | 27 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.